

already exhibited high efficacy against MM cells in recent *in vitro* studies.

Potential Commercial Applications:

- Therapeutic Uses
 - Use as an unconjugated antibody
 - Use as a targeting moiety for immunoconjugates such as CARs, ADCs, immunoconjugates, bispecific antibodies, etc.
- Diagnostic agent for detecting and monitoring BCMA-expressing malignancies

Value Proposition:

- First to market potential—There are no current targeted therapeutics for BCMA
 - High specificity and binding to BCMA results in less non-specific cell killing, therefore fewer potential side-effects for the patient
 - Chimeric Antigen Receptor-based therapies have been successful against B-cell lineage cancer; an anti-BCMA CAR represents a highly effective therapeutic candidate
- Development Stage: In-vitro testing.
Inventor(s): Ira Pastan (NCI), Tapan Bera (NCI), Satoshi Nagata (Sanford Research Center), and Tomoko Ise (Sanford Research Center).

Intellectual Property:

US Provisional Application 62/255,255 (HHS Reference No. E-010-2016/0-US-01) filed November 13, 2015 entitled “Anti-BCMA Polypeptides and Conjugates”;

US Provisional Application 62/257,493 (HHS Reference No. E-010-2016/1-US-01) filed November 19, 2015 entitled “Anti-BCMA Polypeptides and Proteins”

Contact Information: Requests for copies of the patent application or inquiries about licensing, and co-development research collaborations should be sent to John D. Hewes, Ph.D. email: john.hewes@nih.gov or phone: 240-276-5515.

Dated: June 20, 2016.

John D. Hewes,

Technology Transfer Specialist, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2016-15057 Filed 6-24-16; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Eye Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Eye Institute Special Emphasis Panel; NEI Clinical Cooperative Agreement Applications.

Date: July 25, 2016.

Time: 11:00 a.m. to 1:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute of Health, 5635 Fishers Lane, Rockville, MD 20852 (Telephone Conference Call).

Contact Person: Brian Hoshaw, Ph.D., Scientific Review Officer, National Eye Institute, National Institutes of Health, Division of Extramural Research, 5635 Fishers Lane, Suite 1300, Rockville, MD 20892, 301-451-2020, hoshaw@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS)

Dated: June 21, 2016.

Natasha M. Copeland,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2016-15062 Filed 6-24-16; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel, F30 Conflict Review.

Date: July 7, 2016.

Time: 1:00 p.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

Contact Person: Elizabeth Webber, Ph.D., Scientific Review Administrator, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3204, MSC 9529, Bethesda, MD 20892-9529, 301-496-1917, webbere@mail.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Small Vessel Vascular Contributions to Cognitive Impairment and Dementia, (VCID) Biomarkers.

Date: July 13, 2016.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesda North Marriott Hotel and Conference Center, 5701 Marinelli Road, Bethesda, MD 20852.

Contact Person: Joel Saydoff, Ph.D., Scientific Review Administrator, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3204, MSC 9529, Bethesda, MD 20892-9529, 301-496-9223, Joel.saydoff@nih.gov

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: June 21, 2016.

Sylvia L. Neal,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2016-15070 Filed 6-24-16; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF THE INTERIOR

National Park Service

[NPS-WASO-NRNL-21277: PPWOCRADIO, PCU00RP14.R50000]

National Register of Historic Places; Notification of Pending Nominations and Related Actions

AGENCY: National Park Service, Interior.
ACTION: Notice.

SUMMARY: The National Park Service is soliciting comments on the significance of properties nominated before June 4, 2016, for listing or related actions in the National Register of Historic Places.

DATES: Comments should be submitted by July 12, 2016.

ADDRESSES: Comments may be sent via U.S. Postal Service to the National